Key points are not available for this paper at this time.
A spectrum of diseases formerly known as histiocytosis X and now called Langerhans-cell histiocytosis is characterized by ERK pathway activation (including BRAF V600E mutations) and diverse clinical manifestations involving bone, skin, lung, and pituitary.
Allen et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: